Abstract
Molecular profiling of cancers can potentially yield novel gene markers of therapeutic prediction, which would aid our ability to tailor targeted therapy regimens specific to each patient. Public data from gene expression profiling may yield clues as to what oncogenic signaling pathways are deregulated in cancers, and what drugs may effectively counteract the aberrant gene regulation patterns observed. Data are also available on panels of cancer cell lines, which have been both profiled at the gene expression level and extensively characterized for drug responses, allowing us to identify geneto- drug correlations. Profiling tumors from patients undergoing adjuvant or neoadjuvant drug treatment can also yield markers of therapeutic response. In this review, we will examine recent studies aimed at our eventually being able to use the molecular profile of a tumor to predict drug response. The profiling data from these studies is publicly available, and can be re-examined by researchers with different questions in mind, offering us a large number of biomarker candidates that could potentially be tested in the clinical setting.
Keywords: Gene expression profiling, oncogenic signatures, drug response prediction, molecular profile of a tumor, gene regulation, CONNECTIVITY MAP, oncogenic signaling pathways, ER+) breast tumors, biomarkers, gene transcription.
Current Drug Targets
Title:Molecular Classification and Drug Response Prediction in Cancer
Volume: 13 Issue: 12
Author(s): Chad J. Creighton
Affiliation:
Keywords: Gene expression profiling, oncogenic signatures, drug response prediction, molecular profile of a tumor, gene regulation, CONNECTIVITY MAP, oncogenic signaling pathways, ER+) breast tumors, biomarkers, gene transcription.
Abstract: Molecular profiling of cancers can potentially yield novel gene markers of therapeutic prediction, which would aid our ability to tailor targeted therapy regimens specific to each patient. Public data from gene expression profiling may yield clues as to what oncogenic signaling pathways are deregulated in cancers, and what drugs may effectively counteract the aberrant gene regulation patterns observed. Data are also available on panels of cancer cell lines, which have been both profiled at the gene expression level and extensively characterized for drug responses, allowing us to identify geneto- drug correlations. Profiling tumors from patients undergoing adjuvant or neoadjuvant drug treatment can also yield markers of therapeutic response. In this review, we will examine recent studies aimed at our eventually being able to use the molecular profile of a tumor to predict drug response. The profiling data from these studies is publicly available, and can be re-examined by researchers with different questions in mind, offering us a large number of biomarker candidates that could potentially be tested in the clinical setting.
Export Options
About this article
Cite this article as:
J. Creighton Chad, Molecular Classification and Drug Response Prediction in Cancer, Current Drug Targets 2012; 13 (12) . https://dx.doi.org/10.2174/138945012803530143
DOI https://dx.doi.org/10.2174/138945012803530143 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Gene Therapy Targeting Nuclear Factor-κB: Towards Clinical Application in Inflammatory Diseases and Cancer
Current Gene Therapy CB1 Cannabinoid Receptors and their Associated Proteins
Current Medicinal Chemistry Pleiotropic Effects of Cardioactive Glycosides
Current Medicinal Chemistry On the Role of Rab5 in Cell Migration
Current Molecular Medicine Current Management of Neonatal Liver Tumors
Current Pediatric Reviews Cholesterol and Apoe: A Target for Alzheimers Disease Therapeutics
Current Drug Targets - CNS & Neurological Disorders Estrogen Receptor Modulators: Relationships of Ligand Structure, Receptor Affinity and Functional Activity
Current Topics in Medicinal Chemistry Gold(III) Complexes in the Oncological Preclinical Arena: From Aminoderivatives to Peptidomimetics
Current Topics in Medicinal Chemistry Kinase Inhibitors as Potential Therapeutics for Acute and Chronic Neurodegenerative Conditions
Current Pharmaceutical Design Anti-Cancer Effects of Citalopram on Hepatocellular Carcinoma Cells Occur via Cytochrome C Release and the Activation of NF-kB
Anti-Cancer Agents in Medicinal Chemistry Playing Modular Puzzle with Adhesion/Growth-Regulatory Galectins: Design and Testing of a Hybrid to Unravel Structure-Activity Relationships
Protein & Peptide Letters Epigenetics in Alzheimers Disease: a Focus on DNA Modifications
Current Pharmaceutical Design MicroRNAs in Cardiovascular Therapeutics
Current Topics in Medicinal Chemistry Key Role of Mitochondria in Alzheimer’s Disease Synaptic Dysfunction
Current Pharmaceutical Design Repurposing of Anticancer Drugs for the Treatment of Bacterial Infections
Current Topics in Medicinal Chemistry Recombinant Antibody Fragments for Neurodegenerative Diseases
Current Neuropharmacology Erythropoietin: Cytoprotection in Vascular and Neuronal Cells
Current Drug Targets - Cardiovascular & Hematological Disorders KCa3.1 Channels and Glioblastoma: In Vitro Studies
Current Neuropharmacology Glutamine, Glucose and other Fuels for Cancer
Current Pharmaceutical Design Opioid Regulation of Mu Receptor Internalisation: Relevance to the Development of Tolerance and Dependence
CNS & Neurological Disorders - Drug Targets